Amneal Pharmaceuticals reported past third quarter 2026 sales of US$862.68 million with adjusted EPS ahead of analyst estimates, while management lifted full year 2026 net revenue guidance to a range of US$3.15 billion to US$3.25 billion. The latest update highlights stronger contributions from complex generics, specialty brands and biosimilars, alongside reduced asset impairment charges compared with the prior year period. We will examine how Amneal Pharmaceuticals' higher 2026 revenue...
Amneal (AMRX) delivered earnings and revenue surprises of +8.33% and +5.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
(StatePoint) Biological drug products (biologics) -- which can be made of sugars, proteins, living cells, tissues, or a
The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...
Amneal Pharmaceuticals (AMRX) has an average rating of buy and mean price target of $22, according t
Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.
The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.
Amneal Pharmaceuticals (AMRX) said Friday that the US Food and Drug Administration approved its lanr
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch imme
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...
On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]
Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.